Effects of MA 956 superalloy and alpha-alumina particles on some markers of human osteoblastic cells in primary culture.
One of the problems associated with the modern biomaterials used in prostheses is osteolysis, which, although its exact origin is unknown, has been associated with wear particles. Osteoblasts seem to participate directly in this phenomenon. This paper investigates in vitro cellular response to the wear particles from the metal substrate and ceramic covering (alpha-alumina) of a new titanium yttrium aluminum alloy, MA 956, that has been proposed as a biomaterial because of its exceptional mechanical and electrochemical properties. The effect of different sizes (10 and 80 microm) of MA 956 and alpha-alumina particles on osteoblast function was studied in primary human bone cell cultures. Cells were harvested from trabecular bone fragments obtained during knee arthroplasty. Osteoblastic cell response to the particles was measured by assaying C-terminal type I procollagen (PICP), alkaline phosphatase, and osteocalcin secretion, with and without 1.25(OH)(2)D(3) stimulation, in the cell-conditioned medium. Both sizes of MA 956 and alpha-alumina particles decreased PICP secretion in nonstimulated osteoblastic cells, but this secretion was not affected in the cultures stimulated with 1.25(OH)(2)D(3). Only the 10 microm alpha-alumina particles inhibited alkaline phosphatase activity in 1.25(OH)(2)D(3)-stimulated and nonstimulated cultures. The rise in osteocalcin levels after 1.25(OH)(2)D(3) stimulation was lower in the presence of the 10 microm MA 956 particles than in the presence of alpha-alumina particles. Although both materials seem to have directly affected in vitro osteoblastic cell function, the increase in osteocalcin levels after 1.25(OH)(2)D(3) stimulation was lower after exposure to MA 956 particles than the increase observed after exposure to alpha-alumina particles. Therefore, it does not seem that osteocalcin stimulated bone resorption, suggesting that MA 956 would be less likely to provoke osteolysis.
Rodrigo
A M
AM
Investigation Unit Hospital La Paz, Madrid, Spain.
Martínez
M E
ME
Martínez
P
P
Escudero
M L
ML
Ruíz
J
J
Saldaña
L
L
Gómez-García
L
L
Fernández
L
L
del Valle
I
I
Munuera
L
L
D000368:Aged; D000469:Alkaline Phosphatase / Q000378:metabolism; D000497:Alloys / Q000494:pharmacology*; D000535:Aluminum / Q000494:pharmacology*; D000537:Aluminum Oxide / Q000494:pharmacology*; D001672:Biocompatible Materials; D002478:Cells, Cultured; D002516:Ceramics / Q000494:pharmacology; D002857:Chromium / Q000494:pharmacology*; D017077:Culture Media, Conditioned; D006801:Humans; D007501:Iron / Q000494:pharmacology*; D008422:Materials Testing; D010006:Osteoblasts / Q000187:drug effects*; D015675:Osteocalcin / Q000378:metabolism; D010316:Particle Size; D011347:Procollagen / Q000378:metabolism; D014025:Titanium / Q000494:pharmacology*; D015019:Yttrium / Q000494:pharmacology*
D000497:Alloys; D001672:Biocompatible Materials; D017077:Culture Media, Conditioned; C092620:MA 956; D011347:Procollagen; D002857:Chromium; D015675:Osteocalcin; D015019:Yttrium; D000535:Aluminum; D014025:Titanium; D007501:Iron; D000469:Alkaline Phosphatase; D000537:Aluminum Oxide